Literature for anagliptin (S09.003 inhibitor)

(Topics flags: S Structure, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2018

Baira,S.M., Sigalapalli,D.K., Bathini,N.B., R,S. and Talluri,M.V.N.K.
LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin
J Pharm Biomed Anal (2018) 159, 92-99. PubMed Europe PubMed DOI I

2015

Nishio,S., Abe,M. and Ito,H.
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
Diabetes Metab Syndr Obes (2015) 8, 163-171. PubMed Europe PubMed DOI PMC EPMC I
Shinjo,T., Nakatsu,Y., Iwashita,M., Sano,T., Sakoda,H., Ishihara,H., Kushiyama,A., Fujishiro,M., Fukushima,T., Tsuchiya,Y., Kamata,H., Nishimura,F. and Asano,T.
DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-kappaB activation
Am J Physiol Endocrinol Metab (2015) 309, E214-E223. PubMed Europe PubMed DOI I
Watanabe,Y.S., Yasuda,Y., Kojima,Y., Okada,S., Motoyama,T., Takahashi,R. and Oka,M.
Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions
J Enzyme Inhib Med Chem (2015) 30, 981-988. PubMed Europe PubMed DOI S I

2014

Furuta,S., Goto,M., Tamura,M., Yamashita,S., Nakaya,K. and Furuta,Y.
The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation
Drug Res (Stuttg) (2014) 64, 448-448. DOI I
Igarashi,M., Tanji,Y. and Nomura,T.
Effect of anagliptin, a newly-developed dipeptidyl peptidase-4 inhibitor on the change of atherogenic outcomes in patients with type 2 diabetes mellitus
Ther Res (2014) 35, 909-916. I

2013

Ervinna,N., Mita,T., Yasunari,E., Azuma,K., Tanaka,R., Fujimura,S., Sukmawati,D., Nomiyama,T., Kanazawa,A., Kawamori,R., Fujitani,Y. and Watada,H.
Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice
Endocrinology (2013) 154, 1260-1270. PubMed Europe PubMed DOI I
Furuta,S., Smart,C., Hackett,A., Benning,R. and Warrington,S.
Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
Xenobiotica (2013) 43, 432-442. PubMed Europe PubMed DOI I
Furuta,S., Tamura,M., Hirooka,H., Mizuno,Y., Miyoshi,M. and Furuta,Y.
Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs
Eur J Drug Metab Pharmacokinet (2013) 38, 87-96. PubMed Europe PubMed DOI I
Nakaya,K., Kubota,N., Takamoto,I., Kubota,T., Katsuyama,H., Sato,H., Tokuyama,K., Hashimoto,S., Goto,M., Jomori,T., Ueki,K. and Kadowaki,T.
Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet
Metabolism (2013) 62, 939-951. PubMed Europe PubMed DOI I
Tsubamoto,Y. and Goto,M.
Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin
Nihon Yakurigaku Zasshi (2013) 141, 339-349. DOI I

2012

Sunami,Y., Sesoko,S. and Kaku,K.
Pharmacokinetics and pharmacodynamics of single and multiple doses of anagliptin, a novel inhibitor of dipeptidyl peptidase-4
Jpn Pharmacol Ther (2012) 40, 847-858. I
Uchino,H. and Kaku,K.
A novel dipeptidyl peptidase-4 inhibitor, anagliptin, improved the daily blood glucose profile
Jpn Pharmacol Ther (2012) 40, 859-869. I

2011

Kato,N., Oka,M., Murase,T., Yoshida,M., Sakairi,M., Yamashita,S., Yasuda,Y., Yoshikawa,A., Hayashi,Y., Makino,M., Takeda,M., Mirensha,Y. and Kakigami,T.
Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor
Bioorg Med Chem (2011) 19, 7221-7227. PubMed Europe PubMed DOI I